newsfilter
← Latest News
GlobeNewswire·

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients - - On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 - - Planned 4STEPS